Crispr Therapeutics AG vs Iron Mountain Inc — how do they compare? Crispr Therapeutics AG trades at $54.07 (market cap $5.23B), while Iron Mountain Inc trades at $122.41 (market cap $36.44B). The key difference: Iron Mountain Inc is far larger — about 7× Crispr Therapeutics AG's market cap, and Iron Mountain Inc pays a 2.82% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | IRM | |
|---|---|---|
Market Cap | $5.23B | $36.44B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $133.06 |
52-Week Low | $44.34 | $78.86 |
Enterprise Value | $3.65B | $55.85B |
Dividend Yield | — | 2.82% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Iron Mountain Inc is a record management services provider. The firm is organized as a REIT. Most of its revenue comes from its storage business, with the rest coming from value-added services. The firm primarily caters to enterprise clients in developed markets. Its business segments include Global RIM Business
Read more on IRM →